# Other (non-renal) specialties

Landmark trials in other (non-renal specialties) that are nonetheless relevant to many 'renal' patients.  

## Critical care

### Sepsis {#sepsis}

[**SEPSISPAM**](https://www.ncbi.nlm.nih.gov/pubmed/24635770) (2014): ![](Logo_RCT.png){height=1.2em} comparing high- (80--85 mmHg) *vs.* low (65--70 mmHg) MAP targets in septic shock.  No difference in mortality at 28 days. In patients with pre-existing HTN, high-target group required less RRT.  

RCTs testing the complex intervention of early goal-directed therapy:

[**RIVERS et al**](https://www.ncbi.nlm.nih.gov/pubmed/11794169) (2001): ![](Logo_RCT.png){height=1.2em} comparing early goal-directed therapy *vs.* usual care in septic shock (n=263). In-hospital mortality lower in EGDT group.  

[**PRISM meta-analysis**](https://www.ncbi.nlm.nih.gov/pubmed/28320242) (2017): ![](Logo_MET.png){height=1.2em} - patient-level meta-analysis of ProCESS, ARISE and ProMISE trials of EGDT *vs.* usual care in septic shock (n=3723). No benefit (for 90-day mortality) for EGDT.  

See also [section on IV fluids](#fluids).  


## Cardiology {#cardio}

\BeginKnitrBlock{box_landmark}<div class="box_landmark">[**HOPE**](https://www.ncbi.nlm.nih.gov/pubmed/10639539) (2000): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - ramipril *vs.* placebo in high-risk patients with vascular disease or diabetes (but not known HFrEF).  Rampril reduced risk of death, MI and stroke.  
</div>\EndKnitrBlock{box_landmark}

\BeginKnitrBlock{box_landmark}<div class="box_landmark">[**CONSENSUS**](https://www.ncbi.nlm.nih.gov/pubmed/2883575) (1987): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - enalapril *vs.* placebo in NYHA class IV CCF.  Mortality benefit seen in enalapril group.  
</div>\EndKnitrBlock{box_landmark}

[**SOLVD**](https://www.ncbi.nlm.nih.gov/pubmed/2057034) (1991): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - enalapril *vs.* placebo in patients with HFrEF (EF < 0.35) - predominantly NYHA II and III. Enalapril reduced all-cause mortality and rates of hospitalisation for and death from heart failure.  


## Haematology

[**BRIDGE**](https://www.ncbi.nlm.nih.gov/pubmed/26095867) (2015): ![](Logo_RCT.png){height=1.2em} LMWH *vs.* placebo for peri-operative "bridging anticoagulation" in patients warfarinised for AF.  Placebo was non-inferior w.r.t. risk of CVA, VTE or TIA and superior w.r.t. risk of major bleeding.  

